New driver mutations in non-small-cell lung cancer

L.T. Tanoue
Yearbook of Pulmonary Disease
January 1, 2012
10.1016/j.ypdi.2012.01.036
Cited by 835

Abstract

Related Papers

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Joan H. Schiller, David Harrington, Chandra P. Belani et al.|New England Journal of Medicine|2002|5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al.|Science|2007|4.5k
Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma
Stephan W. Morris, Mark N. Kirstein, Marcus B. Valentine et al.|Science|1994|2.4k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman, Liang Chen, Xiaohong Tan et al.|Nature Medicine|2008|1.3k
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten, Andrew L. Faber, Candice L. Horn et al.|Nature|2007|1.3k